Nutriband Inc. (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, announced that it has received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) for trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The notice, dated September 2, moves the trademarks toward registration, a critical step in protecting the product's commercial identity.
The trademarks will be published in the USPTO's Trademark Official Gazette, triggering a 30-day opposition period. If no objections are filed, the USPTO is expected to issue a Notice of Allowance, after which the company can proceed with registration. This development underscores Nutriband's commitment to securing its intellectual property as it advances its fentanyl patch, which incorporates the company's proprietary AVERSA™ abuse-deterrent technology.
The fentanyl patch is designed to deter abuse, misuse, and accidental exposure, addressing a significant public health concern associated with opioid medications. Nutriband has indicated that the product has potential peak annual U.S. sales of $80 million to $200 million, reflecting the substantial market opportunity if approved. The AVERSA™ technology, which can be integrated into any transdermal patch, is already protected by patents issued in 46 countries, providing a strong IP foundation.
This trademark advancement is a key milestone for Nutriband as it prepares for potential commercialization. Securing trademark protection for the product's brand names is essential to establish market recognition and prevent infringement. The company's focus on abuse-deterrent formulations aligns with regulatory and societal pressures to combat opioid misuse, potentially positioning Nutriband favorably with healthcare providers and payers.
Analysts note that abuse-deterrent technologies are a growing segment in pain management, with increasing demand for safer opioid delivery systems. Nutriband's approach, which aims to reduce the risk of accidental exposure and diversion, could offer a competitive edge. However, the product still requires regulatory approval and successful commercialization, which are subject to clinical and market risks.
The company's progress in both patent and trademark protection indicates a strategic effort to build a robust IP portfolio. As the opposition period commences, Nutriband will need to monitor for any challenges. A successful outcome would strengthen its market position and investor confidence.
For more information on Nutriband and its pipeline, visit the company's newsroom at https://ibn.fm/NTRB.
